Angiogenesis is crucial in numerous physiological and pathological processes. In malignancy, both the growth of a primary tumor and its metastatic spread to distant sites require the constant elicitation of host blood vessels by tumor-associated inducer molecules (for review, see refs. 1 and 2). One of these most likely is angiogenin (Ang), a 14.1-kDa protein isolated originally from medium conditioned by HT-29 human colon carcinoma cells (3) and subsequently from normal serum (4) and milk (5) . It is a heparin-binding protein (6) whose threedimensional structure has been determined recently (7) . Ang is homologous in amino acid sequence to pancreatic RNase (8)-although differing markedly in enzymatic activity (9)-and contains distinctive catalytic and cell-binding domains that are essential for its angiogenic activity (10, 11) . It activates intracellular second-messenger pathways (12) , supports tumor and endothelial cell adhesion (6, 13) , and undergoes nuclear translocation (14) . A 42-kDa Ang-binding protein isolated from the surface of cultured bovine endothelial cells has been identified as a smooth muscle type of a-actin (15) (16) (17) . It, like commercial actin preparations, binds tightly not only to bovine but also to mouse and human Ang (G.-F. Hu, personal communication) . The demonstration that both actin and antiactin antibodies inhibit Ang-induced angiogenesis in the chicken embryo chorioallantoic membrane underscores the functional relevance of this interaction (16) .
The inhibition of angiogenesis is an attractive therapeutic target for the treatment of both primary and metastatic cancer.
A preliminary study showed that the growth of HT-29 cells in athymic mice is Ang-dependent and that a specific neutralizing monoclonal antibody (mAb) to human Ang is capable of preventing or delaying the appearance of tumors (18) . The present study, using a more sensitive model system, demonstrates a dramatic increase in the efficacy of mAb 26-2F in preventing the appearance of HT-29 tumors. Furthermore, two additional Ang antagonists, mAb 36u-which differs in epitope specificity from mAb 26-2F-and actin, are equally effective in preventing the establishment of this tumor. Importantly, the capacity of actin to interfere with human tumor growth in the athymic mouse provides a means to investigate both the potential toxicity and the effectiveness of an Ang antagonist under conditions where the antagonist may bind to endogenous mouse Ang. In addition, the data show that the growth of tumors of two different histological types is inhibited by treatment with Ang-neutralizing mAbs.
MATERIALS AND METHODS Materials. Male outbred athymic mice (Crl:nu/nu) were obtained at 5 weeks of age from the isolator bred colony of Charles River Laboratories at Wilmington, MA, and maintained under specific pathogen-free conditions in a temperature-and humidity-controlled environment. The human tumor cell lines HTB-38 colon adenocarcinoma (HT-29), CCL-121 fibrosarcoma (HT-1080), and CCL-185 lung carcinoma (A549) were obtained from the American Type Culture Collection and cultured as described for HT-29 cells (18) . mAbs 26-2F and 36u, both IgGlK mAbs that bind to human Ang with similar affinity, were obtained as described (19) . mAb 26-2F, which recognizes a discontinuous epitope on Ang that encompasses residues 38-41 and 89, neutralizes both the ribonucleolytic and angiogenic activities of Ang (19) . mAb 36u also inhibits these activities of Ang and interacts with a different region of the molecule that includes residues within the segment 58-73 (K.A.O., unpublished results). MOPC 31C, a nonspecific IgGlK-secreting mouse hybridoma, was obtained from the American Type Culture Collection (no. CCL-130). All three immunoglobulins were purified from ascites fluid and quantified by ELISA as described (19) . Bovine muscle a-skeletal actin was purchased from Sigma.
Anti-Tumor Activity in Vivo. This was determined by modifying a described protocol (18 
RESULTS AND DISCUSSION
The earlier study demonstrated that the establishment of HT-29 tumors in athymic mice was delayed significantly and in some cases prevented completely by the administration of the Ang-neutralizing mAb 26-2F (18) . These effects were observed above a threshold dose of mAb dependent on the number of tumor cells injected (i.e., 6 jig for 1 x 106 and 3 ,ug for 5 x 105 tumor cells injected, Table 1 (18) 10-25% of the mice in the mAb 26-2F-treated groups that exhibited successful prevention and delay of tumor growth (P c 0.0001) were tumor-free after treatment, with no significant difference in the percentages of tumor-free mice among these groups (Table 1) . With the modified protocol, 30 ,ug of mAb 26-2F was administered daily for 35 days at the 1.25 x 105 injected cell number. While this regimen is successful in preventing tumors, as indicated by the significant difference in the survivor function as compared with that of the PBS controls (P = 0.0003), the percentage of mice remaining tumor-free, 14%, is well within the range of that obtained previously. However, when mice are treated with 60 Ag of mAb 26-2F, not only is the treatment successful as determined by survival analysis (P < 0.0001), but the percentage of tumorfree mice increases markedly. In this group, in which the ratio of mAb to tumor cells is now increased by 60% above the highest ratio used in the previous protocol, 65% of the mice are tumor-free at the termination of treatment (Table 1) . Comparison of the results obtained with the two different doses of mAb 26-2F in the modified protocol appears to indicate that the increased percentage of tumor-free mice in the 60-,ug dose group is attributable primarily to the increase in mAb/cell ratio and not to other alterations in the protocols-i.e., treatment duration, lower number of tumor cells injected, increased time to tumor appearance. An investigation using several other doses of mAb 26-2F in the two protocols would be required to demonstrate that the increased mAb/cell ratio is both necessary and sufficient to increase the percentage of tumor-free mice. However, the results indicate that the modification of the protocol is successful in providing a more sensitive system in which to test and compare Ang antagonists. or a combined treatment of 30 jig of each of these mAbs) compared with tumors of PBS control mice (P = 0.0038). These data support the proposition that the antitumor effect of treatment with mAbs 26-2F and 36u is due to inhibition of tumor-induced angiogenesis. Interestingly, a decrease in vascular density is accompanied by a concomitant decrease in the amount of tumor necrosis, suggesting a positive correlation between these two variables. Although the exact nature of this relationship has not been established as yet, an increase in necrotic area could result from blood vessel collapse, owing to the higher proliferative state of tumor cells in untreated versus mAb-treated animals (21) .
Actin, a non-mAb Ang Antagonist, Is as Effective as mAbs 26-2F and 36u. Actin, an additional Ang antagonist, was tested for its capacity to delay or prevent tumor growth. It resembles the above anti-Ang mAbs in binding to and neutralizing the angiogenic activity of human Ang (16); indeed, its binding epitope overlaps that of mAb 36u (15) . However, unlike the above mAbs, it also binds to mouse Ang. The combined data from three separate experiments indicate that treatment with actin at a dose of 18 ,ug (the molar equivalent of 60 ,ug of mAb) results in a survivor function that differs significantly from that of the PBS-treated mice (P < 0.0001, Table 2 ), with 63% of the actin-treated mice remaining tumor-free at the end of treatment. There is no evidence of toxic side effects, despite the capacity of this antagonist to interact with and potentially neutralize the endogenous Ang of the mice. Treatment with the actin diluent buffer (2 mM Tris-HCl, pH 8.0/0.2 mM ATP/0.2 mM CaCl2) does not result in any tumor-free mice (n = 20; data not shown). The similarity between the survivor functions for mice treated with actin (Fig. 1B) and for mice treated with anti-Ang mAbs (P > 0.23, Fig. 1A ) is most striking. Tumor-free mice treated with these Ang antagonists were observed for up to 22 weeks after tumor cell injection (median observation time for each experiment = 8 weeks). During this period 93% of these mice remained tumor-free.
Analysis of Delay in the Appearance of Those Tumors That Do Develop in Mice Treated with Ang Antagonists. Previously, doses of mAb 26-2F that resulted in the complete prevention of tumor formation in some mice also delayed tumor appearance in the remaining mice that did develop tumors (18) . In the current study, the small number of tumor-bearing mice in some of the treated groups precludes statistical analysis of possible delay [mAb 26 Although these murine mAbs have been useful in demonstrating these principles, their utility could be limited, of course, by problems known to occur with the use of murine immunoglobulins for human therapy (25) . Humanization of these murine mAbs, however, may circumvent these problems. Un (36) , inhibitory synthetic peptides (37) , and a ribonuclease inhibitor (38) used successfully in preliminary antitumor studies (39) . These Ang antagonists, along with other structurally based Ang antagonists under development based on x-ray crystallography, are the subject of ongoing investigations into the design of clinically effective anti-Ang therapeutics.
